RecruitingNCT06647927

GenLab: Unveiling the Genetic Landscape of Brugada Syndrome: Novel Biomarker Discovery for Precise Diagnosis

Unveiling the Genetic Landscape of Brugada Syndrome: Novel Biomarker Discovery for Precise Diagnosis


Sponsor

IRCCS Policlinico S. Donato

Enrollment

350 participants

Start Date

Dec 2, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This research makes several significant contributions to the field of BrS. It employs advanced genetic sequencing techniques to develop a genetic signature to improve the accuracy and efficiency of BrS diagnosis. The identification of specific biomolecular profiles and genetic signatures enhances our understanding of the syndrome's molecular mechanisms, facilitating targeted therapies and refined risk stratification. These advancements optimize patient care by enabling personalized treatment plans and risk assessment. Overall, this research adds value by advancing diagnostic methods, providing molecular insights, optimizing patient care, and positively impacting public health outcomes in BrS.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Age \> 18 years
  • Patients affected by Brugada Syndrome
  • Patients who signs the Informed Consent

Exclusion Criteria1

  • None

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Irccs Policlinico San Donato

San Donato Milanese, Milan, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06647927


Related Trials